Evidence map›Paper›PMID 37724295›Full record

ArticlePharmacogenomics and personalized medicine2023

Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation.

Yazun Jarrar, Sara Abudahab, Ghasaq Abdul-Wahab, Dana Zaiter, Abdalla Madani, Sara J Abaalkhail, Dina Abulebdah, Hussam Alhawari, Rami Musleh, Su-Jun Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yazun JarrarDepartment of Basic Medical Sciences, Faculty of Medicine, Al-Balqa Applied University, Al-Salt, Jordan.
Sara AbudahabDepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Ghasaq Abdul-WahabDepartment of Oral Surgery and Periodontology, College of Dentistry, Al-Mustansiriya University, Baghdad, Iraq.
Dana ZaiterDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Abdalla MadaniDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Sara J AbaalkhailDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Dina AbulebdahDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
Hussam AlhawariDepartment of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
Rami MuslehDepartment of Pharmacy, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.ORCID 0000-0001-6810-8390
Su-Jun LeeDepartment of Pharmacology, Pharmacogenomics Research Center, College of Medicine, Inje University, Busan, Korea.ORCID 0000-0002-3570-0598

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: N-acetyltransferase 2 (NAT2) enzyme is a Phase II drug-metabolizing enzyme that metabolizes different compounds. Genetic variations in Aim: This study aimed to investigate the association of Methods: We sequenced the whole protein-coding region in Results: This study revealed that the heterozygous Conclusion: The finding in this study suggests that the

Indexed as

genetic variantsJordanian populationN-acetyltransferase 2NAT2triglyceridetype II diabetes mellitus

Identifiers

PMID37724295
PMCPMC10505377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.